Please try another search
For the nine months ended 30 September 2018, Synergy Pharmaceuticals Inc revenues increased from $7.4M to $31.9M. Net loss decreased 46% to $100.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing decrease of 83% to $7.5M (expense), General and administrative - Balancing decrease of 17% to $100.9M (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 11.11 | 12.25 | 8.59 | 9.4 |
Gross Profit | 7.18 | 8.37 | 4.88 | 7.45 |
Operating Income | -29.61 | -29.09 | -38.62 | -38.19 |
Net Income | -34.54 | -29.69 | -36.1 | -36.97 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 83.04 | 96.61 | 132.65 | 166.61 |
Total Liabilities | 179.28 | 161.29 | 171.28 | 172.12 |
Total Equity | -96.24 | -64.69 | -38.63 | -5.52 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 0 Months | 3 Months | 12 Months |
Cash From Operating Activities | -89.08 | -73.49 | -35.75 | -212.89 |
Cash From Investing Activities | -0.19 | -0.19 | -0.1 | -0.21 |
Cash From Financing Activities | -2.07 | -2.07 | -2.47 | 267.7 |
Net Change in Cash | -91.34 | -75.75 | -38.33 | 54.6 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review